+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a non-active cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This phase 2a, double-blind study aims to provide proof-of-concept evidence over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice daily, and the other will apply a matching vehicle cream twice daily for 16 weeks. The study includes approximately 9 visits over about 18 weeks in total, covering treatment and follow-up periods. Throughout the trial, participants will attend scheduled visits for assessments including skin evaluations, photography confirmation of PPP, and various symptom and quality of life measures. Researchers will monitor improvements using the PPP Area and Severity Index PPPASI and Physician Global Assessment PGA, as well as track adverse events and changes in symptoms like itch and pain. The main outcome is the number of participants achieving at least a 75% improvement in PPPASI score after 16 weeks of treatment.

Age: 18Years +All GendersPhase 2
40 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.

Age: 18Years +All GendersPhase 2
80 locations
E

Actively Recruiting

Researchers are evaluating how well the medicine zasocitinib works and its safety in children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis. The study is conducted in two parts Part A includes both children and teenagers, while Part B includes only children. Initially, only teenagers meeting specific study rules can join, with children joining after sufficient data is available from other studies. In Part A, participants are randomly assigned to receive either zasocitinib or a matching placebo orally once daily for the first 16 weeks. After this, all receive zasocitinib until the study ends. In Part B, all children receive weight-based oral doses of zasocitinib throughout the study. The treatment lasts up to 208 weeks, with a total study participation time of up to 217 weeks, including screening and safety follow-up. Participants will visit the study site multiple times during the study for assessments, including skin evaluations and measuring drug levels in the blood. Researchers will monitor how well participants respond using various psoriasis severity scales and quality of life questionnaires. A safety follow-up period of 4 weeks occurs after treatment ends to monitor any ongoing effects. The study aims to understand zasocitinibs effects and safety in this young population over a long term.

Age: 4Years - 17YearsAll GendersPhase 3
39 locations
E

Actively Recruiting

Researchers are evaluating the effects of camoteskimab in adults aged 18 to 65 with moderate-to-severe atopic dermatitis. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of camoteskimab compared to placebo. Participants include those who are treatment-naive or have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week placebo-controlled period where participants are randomly assigned to one of three camoteskimab dose levels or placebo, all administered by subcutaneous injection. In Part 2, an extension period, all participants receive camoteskimab. This design allows comparison of different dose levels and monitoring of long-term treatment effects. Participants will be assessed regularly throughout the study with measures including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak pruritus numerical rating scale PP-NRS. Safety and efficacy will be monitored through these assessments over 24 weeks and beyond. The study includes signing informed consent and adherence tracking, with the primary outcome focused on percentage change in EASI score from baseline to Week 24.

Age: 18Years - 65YearsAll GendersPhase 2
85 locations
E

Actively Recruiting

Researchers are evaluating the safety and efficacy of GIA632 in adults aged 18 to 99 years with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled Phase 2b study aims to identify the optimal dose of GIA632 to be further studied in a Phase 3 program. The study also includes an extension period to assess longer-term safety and effectiveness. Participants will be randomly assigned to one of several groups receiving either GIA632 or a placebo during a 48-week core treatment period. The study will measure the dose-response relationship of GIA632 and compare its effects with placebo. The extension phase will further evaluate the safety and efficacy over a longer term. During the study, participants will have regular assessments including measurement of facial and total body vitiligo area using the Vitiligo Area Scoring Index VASI at baseline and multiple time points up to 48 weeks. Researchers will also track improvements using the Vitiligo Noticeability Scale. Safety and treatment response will be monitored throughout the study period, which lasts up to approximately four years including follow-up.

Age: 18Years - 99YearsAll GendersPhase 2
83 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of baricitinib in treating severe or very severe alopecia areata, a type of hair loss, in children aged 6 to less than 18 years. This Phase 3 trial includes children and adolescents with severe alopecia areata lasting at least one year and aims to understand how baricitinib helps improve their condition compared to placebo. Participants will be randomly assigned to one of three groups baricitinib high dose, baricitinib low dose, or placebo, all taken orally. The study includes a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week post-treatment follow-up. Some participants may qualify for additional treatment after the extension period lasting up to 180 weeks. During the study, participants will have regular assessments including hair loss severity scores, patient and clinician reported outcomes, anxiety and depression scales, and pharmacokinetic tests. Safety and effects on quality of life will be monitored throughout, with follow-ups after treatment ends. Total participation may last several years depending on the study phase and extension.

Age: 6Years - 17YearsAll GendersPhase 3
127 locations
E

Actively Recruiting

Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.

Age: 18Years +All GendersPhase 3
188 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of bimekizumab compared to a placebo in adults with palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This Phase 3 study aims to provide important information about this treatment option in participants who have had PPP for at least 24 weeks and meet specific severity criteria. Participants will be randomly assigned to one of two groups one receiving bimekizumab throughout the study and the other receiving a placebo initially, then switching to bimekizumab during the maintenance phase. The treatments are given at scheduled times, and the study includes an open-label extension period to further assess the treatment. During the study, participants will have regular assessments of their skin condition, including the Palmoplantar Pustulosis-Investigator Global Assessment and Palmoplantar Pustulosis Area Severity Index at weeks 8 and 16. Quality of life and pain levels will also be evaluated. Safety is closely monitored through the recording of any adverse events up to approximately 117 weeks. The total time commitment includes initial treatment and an extended safety follow-up period.

Age: 18Years +All GendersPhase 3
91 locations
E

Actively Recruiting

Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.

Age: 12Years - 63YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of dupilumab in adults with chronic pruritus of unknown origin CPUO, a condition causing severe itching without a clear cause. This Phase 3 study includes two parallel, double-blind clinical trials involving men and women aged 18 to 90 years who have experienced severe itching for at least six months. The trials aim to compare dupilumab with a placebo while both groups also use a non-sedative antihistamine and moisturizer. After up to a 4-week screening, participants with severe itch enter a 4-week run-in period receiving antihistamines and moisturizers. Those still experiencing severe itching are randomly assigned to receive either dupilumab or placebo injections subcutaneously every two weeks for 24 weeks, alongside their existing treatments. Following this, all participants enter a 12-week follow-up period to monitor outcomes. Participants attend regular visits for assessments including itch severity ratings, quality of life questionnaires, and anxiety and depression scales. Researchers will measure changes in itch intensity, sleep disturbance, and life quality over time. Safety is closely monitored throughout the treatment and follow-up periods, with the total participation lasting up to 44 weeks.

Age: 18Years - 90YearsAll GendersPhase 3
94 locations

1-10 of 13

1